Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-22
2005-03-22
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S299000, C514S305000, C514S413000, C540S482000, C546S112000, C546S133000, C548S452000
Reexamination Certificate
active
06869946
ABSTRACT:
The invention provides compounds of Formula I:wherein m1is 0 or 1;m2is 1 or 2;R1is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl;R2is —H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or phenyl, provided that when m1is 1 at least one of R1and R2is —H; or a pharmaceutically acceptable salt, pharmaceutical composition, a pure enantiomer or racemic mixture thereof. The invention also provides a method for treating a disease or condition in a mammal, wherein the α7 nicotinic acetylcholine receptor is implicated and for treating diseases where there is a sensory-gating deficit in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of Formula I. These compounds may be in the form of pharmaceutical salts or compositions, and may be in pure enantiomeric form or may be racemic mixtures.
REFERENCES:
patent: 3702324 (1972-11-01), Skinner et al.
patent: 4093734 (1978-06-01), Kruger et al.
patent: 4593034 (1986-06-01), Munson et al.
patent: 4605652 (1986-08-01), Welstead, Jr.
patent: 4657911 (1987-04-01), Imbert et al.
patent: 4717563 (1988-01-01), Alphin et al.
patent: 4721720 (1988-01-01), Wootton et al.
patent: 4797387 (1989-01-01), King
patent: 4798829 (1989-01-01), King et al.
patent: 4820715 (1989-04-01), Monkovic et al.
patent: 4835162 (1989-05-01), Abood
patent: 4863919 (1989-09-01), Smith
patent: 4870181 (1989-09-01), Lo
patent: 4877780 (1989-10-01), Vega-Noverola et al.
patent: 4908370 (1990-03-01), Naylor et al.
patent: 4910193 (1990-03-01), Buchheit
patent: 4920227 (1990-04-01), Pelletier et al.
patent: 4983600 (1991-01-01), Ward et al.
patent: 5017580 (1991-05-01), Naylor et al.
patent: 5025022 (1991-06-01), Naylor et al.
patent: 5039680 (1991-08-01), Impoerato et al.
patent: 5057519 (1991-10-01), Suberg
patent: 5070095 (1991-12-01), Jagdmann et al.
patent: 5084460 (1992-01-01), Munson, Jr. et al.
patent: 5175173 (1992-12-01), Sun
patent: 5206246 (1993-04-01), Langlois et al.
patent: 5236931 (1993-08-01), Jagdmann et al.
patent: 5237066 (1993-08-01), Dorme et al.
patent: 5273972 (1993-12-01), Jagdmann et al.
patent: 5290938 (1994-03-01), Johansen
patent: 5561149 (1996-10-01), Azria et al.
patent: 5723103 (1998-03-01), De Paulis et al.
patent: 5741819 (1998-04-01), Illig et al.
patent: 5837489 (1998-11-01), Elliott et al.
patent: 5919793 (1999-07-01), Brown et al.
patent: 5977144 (1999-11-01), Meyer et al.
patent: 3810552 (1989-10-01), None
patent: 327335 (1988-02-01), None
patent: 353371 (1990-02-01), None
patent: 2625678 (1988-01-01), None
patent: WO 9109593 (1991-07-01), None
patent: WO 9211259 (1992-07-01), None
patent: WO 9215579 (1992-09-01), None
patent: WO9640100 (1996-12-01), None
patent: WO9730998 (1997-08-01), None
patent: WO 9847481 (1998-10-01), None
patent: WO 0073431 (2000-12-01), None
patent: WO 0129034 (2001-04-01), None
patent: WO 0136417 (2001-05-01), None
patent: WO 0160821 (2001-08-01), None
patent: WO 0185727 (2001-11-01), None
Levin, E.D., Nicotinic acetylcholine involvement in cognitive function in animals, Psychopharmacology, 138:217-230, 1998.*
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 2050-7, 1996.*
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 1992-6, 1996.*
Bannon, A.W.,American Association for the Advancement of Science.Broad-Spectrum, Non-Opiodid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors. vol. 279, No. 5347, pp. 77-81, 1998.
Dineley, K.T., and James W. Patrick,The Journal of Biological Chemistry.Amino Acid Determinants of •7 Nicotinic Acetylcholine Receptor Surface Expression. vol. 275, No. 18, pp. 13974-13985, May 5, 2000.
Eisele, Jean-Luc.Letters to Nature.Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. vol. 366, pp. 479-483, Dec. 2, 1993.
Holladay, Mark W., et al.,Journal of Medicinal Chemistry.Neuronal Nicotine Acetylcholine Receptors as Targets for Drug Discovery. Dec. 19, 1997.
Kem, William R.Behavioral Brain Research.“The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).” 113 (2000) 169-181.
Kuntzweiler, Theresa A., et al.,Drug Development Research.“Rapid Assessment of Ligand Actions with Nicotinic Acetylcholine Receptors Using Calcium Dynamics and FLIPR.” vol. 44, No. 1, pp. 14-20, May 1998.
Macor, JE.Biorganic&Medicinal Chemistry Letters.“The 5-HT3Antagonist Tropisetron (ICS 205-930) is a Potent and Selective α7 Nicotinic Receptor Partial Agonist.” 11 (2001) 319-321.
Groppi, Jr. Vincent E.
Jacobsen Eric Jon
Myers Jason K.
Piotrowski David W.
Walker Daniel Patrick
Dorigo Andrea E.
Ling Lorraine B.
Pfizer Inc
Rao Deepak
Richardson Peter C.
LandOfFree
Substituted azabicyclic moieties for the treatment of disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted azabicyclic moieties for the treatment of disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted azabicyclic moieties for the treatment of disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3451893